1. Memori
  2. ›
  3. Articles

What "A Measles Case in Japan" Actually Means — Imported Cases and Severity After WHO Elimination Certification

3 min read日本語版あり
Audience
Parents who want to verify their child's MR vaccine record; parents preparing for international travel
Target length
~1,300 words
Status
Draft v1 (translated from Japanese v1)
Original
../249_measles.md

TL;DR

  • ·Japan has WHO measles-elimination certification but still sees imported cases regularly — maintaining population-wide vaccination coverage above 95% is what prevents those importations from igniting local spread
  • ·SSPE, a fatal late neurological complication, occurs years after measles infection and carries substantially elevated risk when measles strikes children under two — making pre-age-two protection the clearest justification for timely vaccination
  • ·When vaccination records are missing or incomplete, adding a dose without waiting for serology is generally the approach guidelines support; the risk of an extra dose in an already-immune person is very low

Contents

  1. Lead
  2. Measles Is Not a Mild Disease
  3. What "Elimination" Actually Means
  4. MR Vaccine Effectiveness and Two-Dose Rationale
  5. Before International Travel
  6. Summary
  7. References

Lead

News of a measles exposure at an airport or hospital surfaces in Japan every few years. Japan received WHO measles-elimination certification in 2015 — meaning no sustained domestic transmission chain for 12 or more months — but imported cases, brought back by travelers from endemic regions, occur with regularity.

"Are two vaccine doses enough?" and "What if I can't find the vaccination record?" — before answering either question, it helps to have an accurate picture of what measles actually does when it reaches an unprotected child.


Measles Is Not a Mild Disease

Measles virus spreads through airborne transmission (droplet nuclei: microscopic airborne particles that can remain suspended and infectious for hours after an infected person leaves a room), making it one of the most contagious human pathogens known. A single infectious person in a susceptible population can infect 12–18 others.

In high-income countries, reported rates of severe complications include pneumonia in approximately 5% of cases, encephalitis in 0.1–0.2%, and death in 0.1–0.2% [1]. In settings with widespread vitamin A deficiency, mortality is substantially higher. WHO reported tens of thousands of measles deaths globally even in 2024 [6].

A particularly important long-term complication is subacute sclerosing panencephalitis: a rare but always fatal brain disease caused by persistent measles virus, appearing years after infection (SSPE) — a chronic, progressive neurological disease that develops seven to ten years after measles infection, follows a fatal course, and has no effective treatment. Overall incidence is estimated at 1 in 100,000 to 1 in 10,000 infections, but there are reports suggesting substantially elevated risk when measles occurs under two years of age [4]. This is one of the reasons pediatric prevention before age two matters so much.


What "Elimination" Actually Means

WHO measles-elimination certification means no sustained domestic transmission for 12 consecutive months — not zero imported cases. Sporadic importations from epidemic regions (which have varied over time: the Philippines, Ukraine, and parts of Europe have been sources at various points) represent a continuing risk [6].

Japan experienced cluster outbreaks in multiple prefectures in 2019, traced to imported cases. The typical propagation pattern: contact on an aircraft, secondary transmission in a hospital setting. Maintaining herd immunity: population-wide protection that occurs when enough individuals are immune to prevent a pathogen from spreading, protecting those who cannot be vaccinated requires vaccination coverage of at least 95%; any pocket of unvaccinated individuals becomes a foothold for an imported case to spread [1].


MR Vaccine Effectiveness and Two-Dose Rationale

The two-dose measles-containing vaccine (MR, measles-rubella) is 95–99% effective at preventing disease [1]. Maintaining coverage at this level in the population is the condition required to sustain elimination.

Japan's routine schedule places the first dose at one year of age (first series) and the second dose the year before primary school entry (second series). Confirming that both dates appear in the boshi techo (Maternal and Child Health Handbook) is the immediate practical check.

When vaccination history is unknown or only one dose is documented — including in adults — an additional dose is an option. The risk of an extra dose in a person who is already immune is limited; guidelines from multiple sources generally support vaccination rather than waiting for a serological test when records are uncertain [1].


Before International Travel

If you plan to travel internationally, check measles outbreak activity at your destination in advance and confirm that your child has completed both doses. For travel to high-risk areas, early vaccination of infants aged six to eleven months (outside the routine schedule) is an option — but if this is done, the child will still need two scheduled MR doses beginning at age one.


Summary

Measles remains a risk in Japan despite elimination certification, through imported cases that can trigger local spread. Knowing the complication rates — and the substantially elevated SSPE risk for infants under two — provides the motivation behind completing two vaccine doses. If vaccination records are missing, a conversation with your pediatrician is the starting point; acting is usually better than waiting for confirmation.


References

  1. Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 7th ed. Philadelphia: Elsevier; 2018.
  2. Mina MJ, Metcalf CJE, de Swart RL, Osterhaus ADME, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348(6235):694–699. doi:10.1126/science.aaa3662. PMID: 25954009.
  3. National Institute of Infectious Diseases (Japan). Measles surveillance data. IASR. 2024.
  4. Buchanan R, Bonthius DJ. Measles virus and associated central nervous system sequelae. Semin Pediatr Neurol. 2012;19(3):107–114. doi:10.1016/j.spen.2012.02.003. PMID: 22889558.
  5. de Swart RL, Ludlow M, de Witte L, et al. Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog. 2007;3(11):e178. doi:10.1371/journal.ppat.0030178. PMID: 18020706.
  6. WHO. Measles. Fact sheet. 2024.

There's more in the Memori app.

Your child's records and deeper reading — all in one place.

See everything in the app
← PreviousFrom "Everyone Gets It" to "Most Don't Anymore" — Varicella Vaccination in Japan Since 2014Next →Rubella Isn't Just Your Problem — Congenital Rubella Syndrome and the Logic of Herd Protection

Related

  • Should the Mumps Vaccine Stay "Optional"? — Hearing Loss Risk and Vaccination Coverage
  • Before the Baby Gets Whooping Cough — The Cocooning Strategy and Booster Vaccination for Families
  • Pool Fever Isn't Only a Summer Thing — A Complete Picture of Adenovirus Infection